Riskpilot← Back to searchSign inGet full accessVECTRON BIOSOLUTIONS AS
ASActiveOrg 992779837Uglavegen 93, 7025 TrondheimResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20086 employees
Revenue 2024
NOK 2M
-62% vs 2023
EBITDA margin
-463.4%
-14% vs 2023
Equity ratio
44.3%
Financial strength
Net profit 2024
NOK -12,7M
-2% vs 2023
| Revenue | NOK 2M | -62% |
| EBITDA | NOK -9,5M | -14% |
| Net profit | NOK -12,7M | -2% |
| Total assets | NOK 21,6M | -20% |
| Equity | NOK 9,6M | -57% |
| Employees | 6 | — |
Legal name
VECTRON BIOSOLUTIONS AS
Org number
992779837
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. juli 2008
Share capital
NOK 3 625 284
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Styrets leder og ett styremedlem i fellesskap. Daglig leder og styrets leder i fellesskap.
Company purpose
Forske og utvikle teknologier for produksjon av rekombinante proteiner og kommersialisering herav, samt utføre tjenester og annen virksomhet som står i naturlig forhold til dette. Selskapet kan også eie aksjer i andre selskaper.
Address
Uglavegen 93, 7025 Trondheim
Email
info@vectronbiosolutions.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 317 | 774 | 556 | 1 233 | 963 | 674 | 215 | 625 | 1 522 | 2 679 | 2 681 | 3 509 | 4 148 | 7 309 | 7 569 | 5 424 | 2 041 |
| Staff expenses | −228 | −434 | −780 | −1 298 | −1 096 | −946 | −1 399 | −1 474 | −3 316 | −4 156 | −2 233 | −2 217 | −3 374 | −4 429 | −5 443 | −6 219 | −4 935 |
| EBITDA | −88 | −239 | −1 309 | −1 555 | −1 361 | −1 270 | −2 147 | −1 788 | −4 413 | −6 034 | −2 251 | −48 | −1 390 | −3 652 | −5 019 | −8 303 | −9 457 |
| Depreciation & amort. | −0 | −0 | −0 | −5 | −6 | −6 | −6 | −6 | −6 | −18 | −33 | −833 | −1 313 | −2 188 | −3 048 | −3 405 | −2 828 |
| EBIT | −88 | −239 | −1 309 | −1 560 | −1 367 | −1 276 | −2 152 | −1 794 | −4 419 | −6 051 | −2 284 | −881 | −2 703 | −5 840 | −8 067 | −11 709 | −12 286 |
| Net financials | −1 | 2 | −21 | 4 | 4 | 5 | 3 | −3 | 1 | 18 | 54 | 59 | −208 | 358 | 90 | −2 | −454 |
| Profit before tax | −88 | −236 | −1 330 | −1 556 | −1 363 | −1 271 | −2 149 | −1 797 | −4 417 | −6 033 | −2 230 | −822 | −2 912 | −5 482 | −7 977 | −11 711 | −12 740 |
| Tax | −41 | −67 | −448 | −552 | −459 | −287 | −657 | −332 | −945 | −1 610 | −399 | −224 | −0 | −0 | −0 | 841 | −0 |
| Net profit | −47 | −170 | −882 | −1 005 | −904 | −984 | −1 492 | −1 465 | −3 472 | −4 423 | −1 832 | −598 | −2 912 | −5 482 | −7 977 | −12 551 | −12 740 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 336 | 769 | 1 999 | 2 250 | 2 628 | 3 076 | 3 345 | 4 204 | 11 042 | 18 588 | 16 749 | 15 790 | 15 344 | 45 063 | 39 928 | 27 038 | 21 585 |
| Equity | 270 | 700 | 1 840 | 1 836 | 1 932 | 1 948 | 1 706 | 2 741 | 8 769 | 15 970 | 14 138 | 13 540 | 10 628 | 39 541 | 34 846 | 22 298 | 9 555 |
| Long-term debt | 0 | 0 | 0 | 0 | 250 | 850 | 1 000 | 1 000 | 1 000 | 1 000 | 1 000 | 1 000 | 3 000 | 2 733 | 2 333 | 1 933 | 8 310 |
| Short-term debt | 66 | 69 | 158 | 414 | 446 | 277 | 639 | 462 | 1 273 | 1 618 | 1 611 | 1 250 | 1 716 | 2 789 | 2 749 | 2 807 | 3 720 |
| Total debt | 66 | 69 | 158 | 414 | 696 | 1 127 | 1 639 | 1 462 | 2 273 | 2 618 | 2 611 | 2 250 | 4 716 | 5 522 | 5 082 | 4 740 | 12 030 |
EBITDA margin
-463.4%
This company
15.8%
Market median
-3033% vs market
20082024
Equity ratio
44.3%
This company
38.2%
Market median
+16% vs market
20082024
Return on equity
-133.3%
This company
18.4%
Market median
-824% vs market
20082024
Net profit margin
-624.3%
This company
8.1%
Market median
-7807% vs market
20082024
Asset turnover
0.09×
This company
1.12×
Market median
-92% vs market
20082024
Debt / equity
1.26×
This company
0.62×
Market median
-103% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-05-19 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BA Deputy Member | Deputy Member | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Dynamk Capital Llc | Company | 22.3% | 22.3% | 2024 |
Leiv Eiriksson Nyskaping As | Company | 20.5% | 20.5% | 2024 |
Eidco As | Company | 15.9% | 15.9% | 2024 |
T3s Technologies Inc | Company | 11.2% | 11.2% | 2024 |
Sparebank 1 Smn Invest As | Company | 6.1% | 6.1% | 2024 |
Investitude As | Company | 5.0% | 5.0% | 2024 |
Svanhild Og Arne Musts Fond For Medisinsk Forskning Sti | Company | 2.8% | 2.8% | 2024 |
Helift As | Company | 2.8% | 2.8% | 2024 |
| Individual | 2.4% | 2.4% | 2024 | |
Baf Holding As | Company | 1.9% | 1.9% | 2024 |
| Individual | 1.8% | 1.8% | 2024 | |
| Individual | 1.4% | 1.4% | 2024 | |
Core Competence Ab | Company | 1.4% | 1.4% | 2024 |
Must Invest As | Company | 1.1% | 1.1% | 2024 |
Turtle Invest As | Company | 1.0% | 1.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of VECTRON BIOSOLUTIONS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bjørn Anders Fossum | Deputy Member | 0 companies |
| Tom Edward Pike | Board of Directors | 0 companies |
| Reinhard Vogt | Board of Directors | 0 companies |
| Jan Erik Foss | Board of Directors | 0 companies |
| Trygve Brautaset | Board of Directors | 0 companies |
| Per Arne Eide | Board of Directors | 0 companies |
| Carl-Åke Carlsson | Chairman | 0 companies |